<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d141" origId="Lidocaine"><sentence id="DrugDDI.d141.s0" origId="s0" text="The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension."><entity id="DrugDDI.d141.s0.e0" origId="s0.p1" charOffset="22-38" type="drug" text="local anesthetic"/><entity id="DrugDDI.d141.s0.e1" origId="s0.p3" charOffset="60-71" type="drug" text="epinephrine"/><entity id="DrugDDI.d141.s0.e2" origId="s0.p5" charOffset="75-89" type="drug" text="norepinephrine"/><entity id="DrugDDI.d141.s0.e3" origId="s0.p8" charOffset="112-140" type="drug" text="monoamine oxidase inhibitors"/><entity id="DrugDDI.d141.s0.e4" origId="s0.p10" charOffset="144-169" type="drug" text="tricyclic antidepressants"/><pair id="DrugDDI.d141.s0.p0" e1="DrugDDI.d141.s0.e0" e2="DrugDDI.d141.s0.e1" interaction="false"/><pair id="DrugDDI.d141.s0.p1" e1="DrugDDI.d141.s0.e0" e2="DrugDDI.d141.s0.e2" interaction="false"/><pair id="DrugDDI.d141.s0.p2" e1="DrugDDI.d141.s0.e0" e2="DrugDDI.d141.s0.e3" interaction="true"/><pair id="DrugDDI.d141.s0.p3" e1="DrugDDI.d141.s0.e0" e2="DrugDDI.d141.s0.e4" interaction="false"/><pair id="DrugDDI.d141.s0.p4" e1="DrugDDI.d141.s0.e1" e2="DrugDDI.d141.s0.e2" interaction="false"/><pair id="DrugDDI.d141.s0.p5" e1="DrugDDI.d141.s0.e1" e2="DrugDDI.d141.s0.e3" interaction="true"/><pair id="DrugDDI.d141.s0.p6" e1="DrugDDI.d141.s0.e1" e2="DrugDDI.d141.s0.e4" interaction="false"/><pair id="DrugDDI.d141.s0.p7" e1="DrugDDI.d141.s0.e2" e2="DrugDDI.d141.s0.e3" interaction="true"/><pair id="DrugDDI.d141.s0.p8" e1="DrugDDI.d141.s0.e2" e2="DrugDDI.d141.s0.e4" interaction="false"/><pair id="DrugDDI.d141.s0.p9" e1="DrugDDI.d141.s0.e3" e2="DrugDDI.d141.s0.e4" interaction="false"/></sentence><sentence id="DrugDDI.d141.s1" origId="s1" text="Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine."><entity id="DrugDDI.d141.s1.e0" origId="s1.p14" charOffset="0-14" type="drug" text="Phenothiazines"/><entity id="DrugDDI.d141.s1.e1" origId="s1.p16" charOffset="19-33" type="drug" text="butyrophenones"/><entity id="DrugDDI.d141.s1.e2" origId="s1.p21" charOffset="60-74" type="drug" text="pressor effect"/><entity id="DrugDDI.d141.s1.e3" origId="s1.p22" charOffset="78-89" type="drug" text="epinephrine"/><pair id="DrugDDI.d141.s1.p0" e1="DrugDDI.d141.s1.e0" e2="DrugDDI.d141.s1.e1" interaction="false"/><pair id="DrugDDI.d141.s1.p1" e1="DrugDDI.d141.s1.e0" e2="DrugDDI.d141.s1.e2" interaction="false"/><pair id="DrugDDI.d141.s1.p2" e1="DrugDDI.d141.s1.e0" e2="DrugDDI.d141.s1.e3" interaction="true"/><pair id="DrugDDI.d141.s1.p3" e1="DrugDDI.d141.s1.e1" e2="DrugDDI.d141.s1.e2" interaction="false"/><pair id="DrugDDI.d141.s1.p4" e1="DrugDDI.d141.s1.e1" e2="DrugDDI.d141.s1.e3" interaction="false"/><pair id="DrugDDI.d141.s1.p5" e1="DrugDDI.d141.s1.e2" e2="DrugDDI.d141.s1.e3" interaction="false"/></sentence><sentence id="DrugDDI.d141.s2" origId="s2" text="Concurrent use of these agents should generally be avoided."/><sentence id="DrugDDI.d141.s3" origId="s3" text="In situations when concurrent therapy is necessary, careful patient monitoring is essential."/><sentence id="DrugDDI.d141.s4" origId="s4" text="Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents."><entity id="DrugDDI.d141.s4.e0" origId="s4.p37" charOffset="29-46" type="drug" text="vasopressor drugs"/><entity id="DrugDDI.d141.s4.e1" origId="s4.p45" charOffset="125-139" type="drug" text="oxytocic drugs"/><pair id="DrugDDI.d141.s4.p0" e1="DrugDDI.d141.s4.e0" e2="DrugDDI.d141.s4.e1" interaction="true"/></sentence></document>